CSIMarket Company Name, Ticker, Competitors, else..


Celldex Therapeutics inc   (NASDAQ: CLDX)
Other Ticker:  
 

Celldex Therapeutics inc

CLDX's Fundamental analysis



Celldex Therapeutics Inc 's sales fell by -71.56 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 88

In Vitro & In Vivo Diagnostic Substances industry recorded growth of revenues by 3.39 %

Celldex Therapeutics Inc net loss increased from $-43 millions, to $-47 millions in IV. Quarter 2024,

• More on CLDX's Growth


Celldex Therapeutics Inc
realized a net loss in trailing twelve months.

Celldex Therapeutics Inc realized cash reduction of $ -0.1 per share in trailing twelve-month period.
In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 179.63.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.97.


• More on CLDX's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 140,400
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 4.88
 Tangible Book Value (Per Share $) 11.17

Celldex Therapeutics Inc
realized net loss in trailing twelve months.

Celldex Therapeutics Inc realized cash outflow of $ -0.1per share in trailing twelve-month period.
In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 179.63.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.97.

Celldex Therapeutics Inc Price to Book Ratio is at 1.69 lower than Industry Avg. of 553.62. and higher than S&P 500 Avg. of 0.01

• More on CLDX's Valuation

•  Market Capitalization (Millions $) 1,261
•  Shares Outstanding (Millions) 64
•  Employees 50
•  Revenues (TTM) (Millions $) 7
•  Net Income (TTM) (Millions $) -158
•  Cash Flow (TTM) (Millions $) -6
•  Capital Exp. (TTM) (Millions $) -2
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 140,400
•  Net Income/Employee(TTM) $ -
•  Receivable Turnover Ratio (TTM) 4.88
•  Tangible Book Value (Per Share $) 11.17

•  Market Capitalization (Millions $) 1,261
•  Shares Outstanding (Millions) 64
•  Employees 50
•  Revenues (TTM) (Millions $) 7
•  Net Income (TTM) (Millions $) -158
•  Cash Flow (TTM) (Millions $) -6
•  Capital Exp. (TTM) (Millions $) -2





  Ratio
•   Capital Ratio (MRQ) 18.91
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.06
•  Asset Turnover Ratio (TTM) 0.01
•  Inventory Turnover Ratio (TTM) -





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com